Cervical cancer (CC) is the third most common cancer in women worldwide; however, CC is a preventable disease, and much effort should be done to prevent it. Persistence of high-risk HPV infection is the strongest epidemiologic risk factor for CC, however it is not sufficient for development of the disease it cofactors should be present. In 2004, IARC listed cervical cancer among those causally related to smoking. Smoking interferes with incidence and prevalence of HPV infection and is associated with cervical intraepithelial neoplasia and invasive CC. Multiple factors seem to intervene on cervical carcinogenesis related with tobacco, especially by direct local carcinogenic effect and local immunosuppression. Smoking addition is also closely related with other confounding factors, like unfavorable psychosocial events, systemic immunity, contraception, and nutrition, which got difficult epidemiologic evaluation of smoking role on cervical carcinogenesis. Smoking habits should be taken in account in clinical practice and in research concerning CC.

1. Introduction

Cervical cancer (CC) is the third most common cancer in women, and the seventh overall, with an estimated 530 000 new cases in 2008. More than 85% of the global burden occurs in developing countries, where it accounts for 13% of all female cancers. Cervical cancer is responsible for 275 000 deaths in 2008, about 88% of which occur in developing countries: 53 000 in Africa, 31 700 in Latin America and the Caribbean, and 159 800 in Asia [1]. However, CC is preventable disease, and much effort should be done to prevent it.

It is now well-established that persistence of Human Papillomavirus (HPV) infection is the strongest epidemiologic factor associated with intraepithelial neoplasia and cancer of cervix [2–5], and it is considered a necessary cause for development of the disease but not sufficient. Exogenous or endogenous factors had been identified to, in conjunction with HPV infection, influence the risk for CC. As Castellsagué and Muñoz [6] suggested, cofactors may be classified into three groups: (1) environmental or exogenous cofactors, including use of oral contraceptives (OCs), tobacco smoking, diet, cervical trauma, coinfection with human immunodeficiency virus (HIV) and other sexually transmitted agents; (2) viral cofactors, such as infection by specific types, coinfection with other types, HPV variants, viral load, and viral integration; (3) host cofactors, including endogenous hormones, genetic factors such as human leukocyte antigen and other host factors related to the host’s immune response.

Winkelstein Jr. [7] in 1977 was the first to put the hypothesis that smoking is a risk factor for cervical cancer. Since then, the action of tobacco on cervical carcinogenesis has been a matter of scientific debate.

The objective of this paper is to update the state of the science about smoking and cancer of the cervix.

2. Material and Methods

It was checked up in PubMed/Medline and Embase databases, studies written in English with keywords: cervical cancer; cervix; CIN; HPV; tobacco; smoking and smoke. Only meta-analysis and or multi-institutional studies were considered for analysis.

3. Results

Plummer et al. reported the first multicentric case-control study in 2003 [8]. In analyzing eight studies on invasive
cancer and two on carcinoma in situ, conducted by International Agency for Research on Cancer (IARC), between 1985 and 1997, the authors conclude that ever-smokers have an excess risk of cervical cancer that persists after controlling for the strong effect of HPV and for other potential cofactors of progression from infection to cancer, and they suggest that squamous cell carcinoma of the cervix should be added to the list of tobacco associated cancers, while for adenocarcinoma, further data should be warranted.

In 2004, IARC revisited its previous conclusions and listed cervical cancer among those causally related to smoking [9].

In 2006, a collaborative reanalysis of 12 studies on CC [10], enrolling 8,097 cases of squamous cell carcinoma, 1,374 women adenocarcinoma, and 26,445 women without carcinoma of the cervix, showed that there are no substantial differences between the two most common histological types of invasive cervical cancer with respect to the role of number of sexual partners, age at first intercourse, age at first birth, body mass index, and use of oral contraceptives. The exception was current tobacco smoking, which is associated with an increased risk of squamous cell but not for adenocarcinoma of the cervix, in agreement with other studies [11, 12].

Vaccarella et al. [13] in 2008 reported a pooled analysis of 13 IARC HPV prevalence survey in 11 countries worldwide, carried out between 1993 and 2005. They concluded that current tobacco smoking was associated with a significant, although moderate, increased risk of prevalent HPV infection. Among current smokers, the risk of being HPV-positive increased with increasing number of cigarettes smoked per day, and women who reported to smoke 15 or more cigarettes daily had a 2-fold risk of HPV positivity as compared with never-smokers. These results have shown that smoking habits interfere with prevalence of HPV infection in agreement with reported in previous studies [14–16].

Syrjänen et al. [17], in 2007, in analyzing a cohort of 3,187 women, conclude that cigarette smoking was not an independent risk factor of CIN2+, except for those patients who tested for HR-HPV (high-risk HPV), and current smoking remains an independent predictor for those patients in a multivariate model, in agreement with previous study of Harris et al. in 2004. [18] that found among women with oncogenic HPV infection, smoking was associated with risk for both CIN1 and CIN2-3. Of the three smoking measures (smoking status, pack years of exposure, and number of cigarettes per day), number of cigarettes per day (>10 cigarettes) was the most strongly associated with risk for CIN1 and CIN2-3. In this study, association between cigarettes smoked by day and CIN did not appear to be mediated by an immunologic response. Those studies suggest that smoking has a special adverse effect on HR-HPV driven cervical carcinogenesis.

A recent study [19], published in 2010, conducted on 2,011 women, 15–19 years old, recruited from 1988 to 1992 then regularly followed until 1997, concluded that there is no evidence to suggest that the risk of acquiring a HPV infection of any type, or a HPV16 or HPV18 infection, increases with either pack years of exposure to smoking or duration of current smoking episode, suggesting that smoking is not a important risk factor for HR-HPV infection.

Xi et al. in 2009 [20] reported an analysis of 1,050 women HPV16 and/or HPV18 positives for viral DNA load, enrolled into the ASCUS-LSIL Triage Study. The authors concluded that higher HPV16 and HPV18 DNA load was associated with status of current, but not former, smoker. Among current smokers, the viral load did not appear to vary appreciably by the intensity and duration of cigarette smoking, in accordance, with previous study of Gunnell et al. [21] in 2006, that in testing for HPV16 DNA presence in first archival cervical smears from 375 cases of in situ cervical squamous carcinoma (CIS) and in 363 controls, it was found that current smokers with a high HPV16 viral load at time of first smear were at a particularly increased risk (27-fold) compared with current smokers without HPV-infection.

4. Discussion

Some molecular mechanisms have been suggested through why smoking may contribute towards cervical carcinogenesis: one involves direct exposure of the deoxyribonucleic acid (DNA) in cervical epithelial cells to nicotine and cotinine, and the other involves exposure to metabolic products resulting from the reactions of other components of cigarettes such as aromatic polycyclic hydrocarbons and aromatic amines. [22, 23]. Cervical mucus of smokers contains measurable amounts of cigarette constituents and their metabolites such as benzo[a]pyrene (BaP) [24], nicotine, and nicotine derived nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [25]. BaP up regulation of HPV genome amplification may increase the probability of viral DNA integration into the host genome, a milestone in the development of cervical cancer [26]. The in vivo effects of long-term nicotine exposure could affect persistent cellular proliferation, inhibition of apoptosis, and stimulation of vascular endothelial growth factor, with increased microvessel density [27]. Other mechanisms that may explain smoking-related carcinogenesis are related with abnormalities in the systemic and peripheral immune systems of smokers, that include unbalanced systemic production of pro- and anti-inflammatory cytokines [28], elevated numbers of cytotoxic/suppressor T lymphocytes, suppression of T lymphocyte activity, diminished numbers of helper T lymphocytes, decreased numbers of natural killer lymphocytes and low levels of immunoglobulins other than immunoglobulin E (IgE) [29]. These effects may result from substantial decreased numbers of Langerhans cells in the cervix of smokers [30, 31]. Aberrant HPV-induced DNA methylation may be another mechanism to explain cervical smoking-related carcinogenesis. In vitro studies in untransformed and transformed cell lines show that short-term exposure to nicotine or cigarette smoke extract is followed by changes in the expression of the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B. Aberrant methylation of the tumour suppressor gene, p16 (CDKN2A), is strongly associated with current smoking in women with squamous cell cervical cancers and high-grade CIN [32].
Intriguing studies analyzing wood-smoke effect on cervical carcinogenesis have shown that, among HPV-positive women, a dose-response relationship is observed for exposure to wood smoke and cervical cancer that persisted in multivariate analysis [33], and chronic exposure to wood smoke significantly increased the risk of CIN III, suggesting that chronic inhalation of carcinogens derived from wood smoke could have an effect on the progression to cervical cancer, similar to that observed for cigarette smoking [34]. Probably the smoking effect on cervical carcinogenesis is not tobacco-specific.

Smoking seems to affect negatively the early natural history of HPV infections. The regression of Low Squamous Intraepithelial Lesions (LSIL) within 2 years is significantly lower in smokers than in never-smokers [35]. Smoking affecting clearance HPV infection remains a conflicting issue. For some authors, smoking has no influence in duration of HPV infection [19], for others tobacco delays the clearance of HPV infection [36, 37].

Covalent alteration of DNA to form DNA adducts is considered an early step in chemical carcinogenesis and, therefore, detection of DNA adducts provides evidence of exposure of the cervix to carcinogens. Prokopczyk et al. [38] had shown, in accordance with previous studies, that significantly higher DNA adduct levels are present in the cervix of smokers as compared with nonsmokers, providing molecular evidence of smoking-related carcinogenic agents that affects the DNA of the cervical epithelium. However, the authors reported no significant differences in smoking-related DNA damage (DNA adduct levels) between HPV-positive and HPV-negative smokers, suggesting that smoking DNA damage is not related with HPV infectivity.

Genetic susceptibility to smoking is an important issue. Cervical cancer risk in smokers may be modified by genetic variants, as that described to interleukin 2 [39] or to 8q24 chromosome polymorphisms [40]. In a recent study [41], the tumor suppressors p53, the fragile histidine triad and the interleukin-10 were under-expressed, and the cyclooxygenase-2 and the Ki-67 were over-expressed in smoking, compared with nonsmoking women with CIN.

Familial and social factors are determinant for smoking attitudes. Being older, being divorced, having friends/family who smoke, and having parents who smoke are all associated with ever smoking, and friends are the primary factor influencing ever smoking, especially among younger women [42]. Smokers seem to have lower compliance for cervical cancer screening, the most powerful weapon against cervical cancer mortality. Smokers held less positive attitudes towards cervical screening than did nonsmokers [43], and the level of nicotine dependence is also significantly related to compliance with screening recommendations; women with higher levels of dependence are less likely to be compliant [44].

Unhealthy life style, negatively rated life events, lack of social support, coping style, and distress, often associated with smoking, alcohol abuse, and illegal drugs addition, have been reported as risk factors for cervical cancer [45–47], especially among low-educated women [48, 49].

Hormonal contraception is implicated on cervical cancer development. Appleby et al. [50], in analyzing 24 studies worldwide that included 16,573 women with cervical cancer and 35,509 without cervical cancer, concluded that the relative risk of cervical cancer is increased in current users of oral contraceptives, and that increased risk is higher in current smokers women.

Nutrition is another important factor that seems to influence cervical carcinogenesis. Oxidative stress induced by deficiencies in antioxidant micronutrients is likely to change normal redox balance and transform the HPV-infected cells toward a carcinogenic process in the cervix [51]. Folate is a well-studied micronutrient with effect on cervical carcinogenesis. Reduced immunocompetence associated with deficiencies of folate and vitamin B12 could increase the risk of infection and persistence with multiple types or higher viral loads of HR-HPVs [52–54].

Higher prevalence rates of HPV have also been found in HIV-seropositive women, proportional to their level of immunosuppression [55–57]. HIV-seropositive women, and particularly the current smokers, are at significantly elevated risk for the development and recurrence of precancerous and cancerous cervical disease [58, 59], especially those who have lower levels of TH cells. It has been shown that TH cells are involved in the defense against HPV-transformed cells [60]. Hence, immunosuppression in general, and depletion of TH cells in particular, may interact with HPV infection to increase the risk of cervical cancer. Marijuana usage is another described factor that potencies tobacco immunosuppression [61].

Smoking also affects survival among women diagnosed with cervical cancer. Recently, Coker et al. [62], in analysing 2661 women diagnosed with invasive cervical cancer from 1995–2005, found that, after adjustment for age and stage at diagnosis, cell type, rural residence, race, insurance coverage, and treatment-received, current smoker, were 35% more likely to die of any cause and 21% more likely to die of cervical cancer compared with known nonsmoking cases, in accordance with previous studies. Unfortunately, few smokers with cervical cancer quit or decreased consumption during treatment [63].

5. Conclusions

All meta-analyses and multi-institutional studies point out that smoking is an important cofactor for cervical squamous cancer and probably also for cervical adenocarcinoma.

Acquisition of HR-HPV infection seems to be a smoking independent event; however, progression of the acquired infection is negatively affected by current smoking. Former smoking seems to be no so important.

The action mechanisms of smoking on HPV driven cervical carcinogenesis seem to be complex and multifactorial. In current smokers, genetic, immunologic, and dietary factors may be associated with cervical epithelium susceptibility for HPV carcinogenic effect, but women’s unhealthy lifestyles seem to be major factors associated with cervical carcinogenesis. What is much determinant for cervical cancer
susceptibility: tobacco action by its own or women health or behaviour associated with smoking habits? Until now, a scientific-based answer is lacking. Epidemiologic, clinical, and laboratorial research is needed to elucidate this unsolved topic.

In order to prevent cervical cancer and to improve therapy results, the practitioner should understand negative effects of tobacco on cervical carcinogenesis, and in those current smoking women with diagnosis of cervical HPV infection or CIN, and he must have an active intervention to invite them to quit smoking habits.

The researchers on cervical cancer should be aware that smoking habits are a major cofactor on cervical HPV driven carcinogenesis, and an important confounder factor for research. Smoking effects should be taken in account by all researchers in their studies.

Conflict of Interests

The author has no conflict of interests that are directly relevant to the content of this paper.

References

[1] “Globocan 2008, cancer facts sheet,” http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
[2] F. X. Bosch, A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002.
[3] N. Munoz, F. X. Bosch, S. Desanjoze et al., “The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain,” International Journal of Cancer, vol. 52, no. 5, pp. 743–749, 1992.
[4] M. H. Schiffman, H. M. Bauer, R. N. Hoover et al., “Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia,” Journal of the National Cancer Institute, vol. 85, no. 12, pp. 958–964, 1993.
[5] J. M. Walboomers, M. V. Jacobs, M. M. Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” Journal of Pathology, vol. 189, no. 1, pp. 12–19, 1999.
[6] X. Castellsagué and N. Muñoz, “Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking,” Journal of the National Cancer Institute, no. 31, pp. 20–28, 2003.
[7] W. Winkelstein Jr., “Smoking and cancer of the uterine cervix: hypothesis,” American Journal of Epidemiology, vol. 106, no. 4, pp. 257–259, 1977.
[8] M. Plummer, R. Herrero, S. Franceschi et al., “Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study,” Cancer Causes and Control, vol. 14, no. 9, pp. 805–814, 2003.
[9] International Agency for Research on Cancer, Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 83 of Tobacco Smoke and Involuntary Smoking, IARC Press, Lyon, France, 2004.
[10] International Collaboration of Epidemiological Studies of Cervical Cancer, “Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies,” International Journal of Cancer, vol. 120, pp. 885–891, 2006.
[11] X. Castellsagué, M. Díaz, S. de Sanjosé et al., “Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention,” Journal of the National Cancer Institute, vol. 98, no. 5, pp. 303–315, 2006.
[12] A. B. González, S. Sweetland, and J. Green, “Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis,” British Journal of Cancer, vol. 90, no. 9, pp. 1787–1791, 2004.
[13] S. Vaccarella, R. Herrero, P. J. F. Snijders et al., “Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV prevalence surveys,” International Journal of Epidemiology, vol. 37, no. 3, pp. 536–546, 2008.
[14] J. W. Sellos, J. B. Mahony, J. Kaczorowski et al., “Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada, Survey of HPV in Ontario Women (SHOW) group,” Canadian Medical Association Journal, vol. 163, no. 5, pp. 503–508, 2000.
[15] H. M. Bauer, A. Hildesheim, M. H. Schiffman et al., “Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon,” Sexually Transmitted Diseases, vol. 20, no. 5, pp. 274–278, 1993.
[16] K. Syrjänen, I. Shabalova, N. Petrovichev et al., “Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN,” European Journal of Epidemiology, vol. 22, no. 10, pp. 723–735, 2007.
[17] K. Syrjänen, I. Shabalova, N. Petrovichev et al., “Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN,” European Journal of Epidemiology, vol. 22, no. 10, pp. 723–735, 2007.
[18] T. G. Harris, S. H. Kulasingam, N. B. Kiviat et al., “Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia,” American Journal of Epidemiology, vol. 159, no. 9, pp. 834–842, 2004.
[19] S. Collins, T. P. Rollason, L. S. Young, and C. B. I. Woodman, “Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study,” European Journal of Cancer, vol. 46, no. 2, pp. 405–411, 2010.
[20] L. F. Xi, L. A. Koutsky, and P. E. Castle, “Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 12, pp. 3490–3496, 2009.
[21] A. S. Gunnell, T. N. Tran, and A. Torrång, “Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 11, pp. 2141–2147, 2006.
[22] A. M. Simons, D. H. Phillips, and D. V. Coleman, “Damage to DNA in cervical epithelium related to smoking tobacco,” British Medical Journal, vol. 306, no. 6890, pp. 1444–1448, 1993.
[23] D. Hellberg, S. Nilsson, N. J. Haley, D. Hoffman, and E. Wnder, “Smoking and cervical intraepithelial neoplasia: nicotine and cotinine in serum and cervical mucus in smokers and nonsmokers,” American Journal of Obstetrics and Gynecology, vol. 158, no. 4, pp. 910–913, 1988.
[24] A. A. Melikian, P. Sun, B. Prokopczyk et al., “Identification of benzo[a]pyrene metabolites in cervical mucus and DNA
adducts in cervical tissues in humans by gas chromatography-mass spectrometry," Cancer Letters, vol. 146, no. 2, pp. 127–134, 1999.

[25] B. Prokopczyk, J. E. Cox, D. Hoffmann, and S. E. Waggoner, “Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers,” Journal of the National Cancer Institute, vol. 89, no. 12, pp. 868–873, 1997.

[26] S. Alam, M. J. Conway, H. S. Chen, and C. Meyers, “The cigarette smoke carcinogen benzo[a]pyrene enhances human papillomavirus synthesis,” Journal of Virology, vol. 82, no. 2, pp. 1053–1058, 2008.

[27] E. R. Gritz, C. Dresler, and L. Sarna, “Smoking, the missing drug interaction in clinical trials: ignoring the obvious,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 10, pp. 2287–2293, 2005.

[28] A. Zeidel, B. Beilin, I. Yardeni, E. Mayburd, G. Smirnov, and H. Bessler, “Immune response in asymptomatic smokers,” Acta Anaesthesiologica Scandinavica, vol. 46, no. 8, pp. 959–964, 2002.

[29] J. D. Johnson, D. Houchens, W. M. Kluwe, D. K. Craig, and G. L. Fisher, “Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: a review,” Critical Reviews in Toxicology, vol. 20, no. 5, pp. 369–395, 1990.

[30] W. A. Poppe, M. Drijoningen, P. S. Ide, J. M. Lauweryns, and F. A. Van Assche, “Langerhans’ cells and L1 antigen expression in normal and abnormal squamous epithelium of the cervical transformation zone,” Gynecologic and Obstetric Investigation, vol. 41, no. 3, pp. 207–213, 1996.

[31] S. E. Barton, P. H. Maddox, D. Jenkins, R. Edwards, J. Cuzick, and A. Singer, “Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change?” Lancet, vol. 2, no. 8612, pp. 652–654, 1988.

[32] J. S. Lea, R. Coleman, A. Kurien et al., “Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis,” American Journal of Obstetrics and Gynecology, vol. 190, no. 3, pp. 674–679, 2004.

[33] A. Ferrera, J. P. Velema, and M. Figueroa, “Co-factors related to the causal relationship between human papilloma virus and invasive cervical cancer in Honduras,” International Journal of Epidemiology, vol. 29, pp. 817–825, 2000.

[34] J. P. Velema, A. Ferrera, M. Figueroa et al., “Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in Honduras,” International Journal of Cancer, vol. 97, no. 4, pp. 536–541, 2002.

[35] K. Matsumoto, A. Oki, R. Furuta et al., “Tobacco smoking and regression of low-grade cervical abnormalities,” Cancer Science, vol. 101, no. 9, pp. 2065–2073, 2010.

[36] A. R. Giuliano, R. L. Sedjo, D. J. Roe et al., “Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States),” Cancer Causes and Control, vol. 13, no. 9, pp. 839–846, 2002.

[37] J. Koskiol, J. Schroeder, D. J. Jamieson et al., “Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women,” American Journal of Epidemiology, vol. 164, no. 2, pp. 176–183, 2006.

[38] B. Prokopczyk, J. E. Cox, D. Hoffmann, and S. E. Waggoner, “Identification of tobacco specific carcinogen in the cervical mucus of smokers and nonsmokers,” Journal of the National Cancer Institute, vol. 89, no. 12, pp. 868–873, 1997.

[39] S. K. Hussain, M. M. Madeleine, L. G. Johnson et al., “Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 7, pp. 1790–1799, 2008.

[40] S. L. Park, S. C. Chang, L. Cai et al., “Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 11, pp. 3193–3202, 2008.

[41] R. Samir, A. Asplund, T. Tot, G. Pekar, and D. Hellberg, “Tissue tumor marker expression in smokers, including serum cotinine concentrations, in women with cervical intraepithelial neoplasia or normal squamous cervical epithelium,” American Journal of Obstetrics and Gynecology, vol. 202, no. 6, pp. 579.e1–579.e7, 2010.

[42] D. L. Oh, J. E. Heck, C. Dresler et al., “Determinants of smoking initiation among women in five European countries: a cross-sectional survey,” Public Health, vol. 10, pp. 74–85, 2010.

[43] T. M. Marteau, M. Hanksins, and B. Collins, “Perceptions of risk of cervical cancer and attitudes towards cervical screening: a comparison of smokers and non-smokers,” Family Practice, vol. 19, no. 1, pp. 18–22, 2002.

[44] M. M. Byrne, E. P. Davila, W. Zhao et al., “Cancer screening behaviors among smokers and non-smokers,” Cancer Epidemiology, vol. 34, no. 5, pp. 611–617, 2010.

[45] E. S. Tiersma, M. L. van der Lee, B. Garssen et al., “Psychosocial factors and the course of cervical intra-epithelial neoplasia: a prospective study,” Gynecologic Oncology, vol. 97, no. 3, pp. 879–886, 2005.

[46] E. S. Tiersma, M. L. van der Lee, A. A. Peters et al., “Psychosocial factors and the grade of cervical intra-epithelial neoplasia: a semi-prospective study,” Gynecologic Oncology, vol. 92, no. 2, pp. 603–610, 2004.

[47] A. L. Coker, C. Hopenhayn, C. P. de Simone, H. M. Bush, and L. Crofford, “Violence against women raises risk of cervical cancer,” Journal of Women’s Health, vol. 18, no. 8, pp. 1179–1185, 2009.

[48] J. E. Wilkerson, J. M. Bailey, E. Mary, M. E. Bieniasz, and M. T. Ruffin, “Psychosocial factors in risk of cervical intraepithelial lesions,” Journal of Women’s Health, vol. 18, no. 4, pp. 513–518, 2009.

[49] S. Franceschi, M. Plummer, G. Clifford et al., “For the International Agency for Research on Cancer Multicentric Cervical Cancer study groups and the International Agency for Research on Cancer Human Papillomavirus Prevalence Surveys study group: differences in the risk of cervical cancer and human papillomavirus infection by education level,” British Journal of Cancer, vol. 101, no. 5, pp. 865–870, 2009.

[50] P. Appleby, V. Beral, B. A. de Gonzalez, and D. Collin, “Cervical cancer prevention and hormonal contraception,” Lancet, vol. 370, no. 9599, pp. 1591–1592, 2007.

[51] M. Perluigi, A. Giorgi, C. Blazrino et al., “Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8 B, pp. 1809–1822, 2008.

[52] S. Chandra and R. K. Chandra, “Nutrition, immune response, and outcome,” Progress in Food and Nutrition Science, vol. 10, no. 1-2, pp. 1–65, 1986.

[53] A. Dhur, P. Galan, and S. Herberg, “Folate status and the immune system,” Progress in Food and Nutrition Science, vol. 15, no. 1-2, pp. 43–60, 1991.

[54] C. J. Piyathilake, S. Badiga, P. Paul et al., “Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs),”
[55] J. C. Johnson, A. F. Burnett, G. D. Willet, M. A. Young, and J. Doniger, “High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women,” *Obstetrics and Gynecology*, vol. 79, no. 3, pp. 321–327, 1992.

[56] S. H. Vermund, K. F. Kelley, R. S. Klein et al., “High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection,” *American Journal of Obstetrics and Gynecology*, vol. 165, no. 2, pp. 392–400, 1991.

[57] G. Tweddel, P. Heller, M. Cunnane, H. Multhaupt, and K. Roth, “The correlation between HIV seropositivity, cervical dysplasia, and HPV subtypes 6/11, 16/18, 31/33/35,” *Gynecologic Oncology*, vol. 52, no. 2, pp. 161–164, 1994.

[58] R. G. Fruchter, M. Maiman, A. Sedlis, L. Bartley, L. Camilien, and C. D. Arrastia, “Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus,” *Obstetrics and Gynecology*, vol. 87, no. 3, pp. 338–344, 1996.

[59] J. C. Johnson, A. F. Burnett, G. D. Willet, M. A. Young, and J. Doniger, “High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women,” *Obstetrics and Gynecology*, vol. 79, no. 3, pp. 321–327, 1992.

[60] W. M. Kast, M. C. W. Feltkamp, M. E. Ressing, M. P. M. Vierboom, R. M. P. Brandt, and C. J. M. Melief, “Cellular immunity against human papillomavirus associated cervical cancer,” *Seminars in Virology*, vol. 7, no. 2, pp. 117–123, 1996.

[61] J. M. Wallace, J. S. Oishi, R. G. Barbers, M. S. Simmons, and D. P. Tashkin, “Lymphocytic subpopulation profiles in bronchoalveolar lavage fluid and peripheral blood from tobacco and marijuana smokers,” *Chest*, vol. 105, no. 3, pp. 847–852, 1994.

[62] A. L. Coker, C. de Simone, K. S. Eggleston, C. Hopenhayn, J. Nee, and T. Tucker, “Smoking and survival among Kentucky women diagnosed with invasive cervical cancer: 1995–2005,” *Gynecologic Oncology*, vol. 112, no. 2, pp. 365–369, 2009.

[63] S. E. Waggoner, K. M. Darcy, C. Tian, and R. Lanciano, “Smoking behavior in women with locally advanced cervical carcinoma: a gynecologic oncology group study,” *American Journal of Obstetrics and Gynecology*, vol. 202, no. 3, pp. 283.e1–283.e7, 2010.